NX-1607:解除Cbl-b制动,通过MAPK/ERK通路促进T细胞激活
Alex To1, Ryohichi Sugimura2,3
1School of Biomedical Sciences, University of Hong Kong, Hong Kong, Hong Kong.
Journal for immunotherapy of cancer
|December 25, 2025
概括
用NX-1607抑制卡西塔斯B淋巴瘤-b (Cbl-b) 通过向PLCγ1-MAPK/ERK通路来增强T细胞激活. 这一发现为开发抗癌新型免疫疗法提供了关键的见解.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 卡西塔斯B淋巴瘤-b (Cbl-b) 是一种E3泛基因酶,可以负面调节免疫细胞激活.
- 在小鼠中Cbl-b缺乏导致瘤排斥和轻度自身免疫,表明其作为免疫治疗点的潜力.
- NX-1607是一种口服的Cbl-b小分子抑制剂,目前正在I期临床试验中.
研究的目的:
- 阐明NX-1607增强T细胞激活的分子通路.
- 为了识别由Cbl-b抑制调节的关键信号级联.
- 在临床前癌症模型中验证发现.
主要方法:
- 使用NX-1607和各种途径抑制剂治疗的Jurkat T细胞进行高通量药物组合查.
- 评估T细胞激活标记物 (例如CD69) 和蛋白质化 (PLCγ1,HCLS1,ERK).
- 在免疫能力强的B细胞淋巴瘤小鼠模型中进行验证.
主要成果:
- 抑制MAPK/ERK通路的抑制剂减弱了NX-1607介导的T细胞激活.
- SRC家族激酶抑制剂降低了CD69的表达和PLCγ1和HCLS1.1.的酸化.
- 在细胞系和小鼠模型中,NX-1607治疗提高了PLCγ1和ERK酸化的调节.
结论:
- 通过NX-1607抑制Cbl-b,通过PLCγ1-MAPK/ERK信号轴释放T细胞激活.
- 这项研究为基于NX-1607的免疫疗法开发提供了关键的机制性见解.
- 向Cbl-b代表了增强抗瘤免疫力的有希望的策略.
关键词:
一个T细胞细胞.相关概念视频
MAPK Signaling Cascades
7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
T Cell Activation and Clonal Selection
14.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.5K
B Cell Activation and Differentiation
15.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.8K
TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K
Amplifying Signals via Enzymatic Cascade
16.9K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
16.9K
Interactions Between Signaling Pathways
7.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K


